Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIONASDAQ:CORTNASDAQ:TRILNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$38.62+0.7%$34.55$21.62▼$39.67$7.33B1.152.47 million shs2.68 million shsCORTCorcept Therapeutics$69.60+0.9%$72.03$28.04▼$117.33$7.38B0.191.15 million shs972,774 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsVRNAVerona Pharma$84.34-1.4%$67.77$11.79▼$86.59$6.84B0.21.32 million shs1.74 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.73%+12.30%+7.80%+22.33%+37.93%CORTCorcept Therapeutics+0.85%-10.87%-1.22%+25.63%+102.09%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%VRNAVerona Pharma-1.40%+4.34%+21.98%+30.46%+594.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.4053 of 5 stars4.51.00.03.91.93.30.6CORTCorcept Therapeutics4.7238 of 5 stars3.53.00.04.21.94.21.9TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma1.9079 of 5 stars2.61.00.00.04.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$57.0947.83% UpsideCORTCorcept Therapeutics 3.00Buy$138.2598.64% UpsideTRILTrillium Therapeutics 0.00N/AN/AN/AVRNAVerona Pharma 3.11Buy$82.13-2.63% DownsideCurrent Analyst Ratings BreakdownLatest TRIL, CORT, BBIO, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.004/30/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.004/30/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.004/30/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $72.004/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.004/21/2025VRNAVerona PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$80.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$127.42M57.55N/AN/A($7.71) per share-5.01CORTCorcept Therapeutics$685.45M10.77$1.02 per share67.96$4.92 per share14.15TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20VRNAVerona Pharma$118.54M57.69N/AN/A$3.10 per share27.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%7/30/2025 (Estimated)CORTCorcept Therapeutics$106.14M$1.1655.2437.62N/A22.35%24.54%20.24%8/4/2025 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/AVRNAVerona Pharma-$54.37M-$2.00N/A2,811.33N/AN/A-79.54%-43.49%8/14/2025 (Estimated)Latest TRIL, CORT, BBIO, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.674.67CORTCorcept Therapeutics0.013.703.64TRILTrillium TherapeuticsN/A19.8219.82VRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%CORTCorcept Therapeutics93.61%TRILTrillium Therapeutics87.15%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%CORTCorcept Therapeutics20.80%TRILTrillium Therapeutics9.10%VRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million143.29 millionOptionableCORTCorcept Therapeutics300106.05 million83.30 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableVRNAVerona Pharma3081.08 million76.10 millionOptionableTRIL, CORT, BBIO, and VRNA HeadlinesRecent News About These CompaniesRFG Advisory LLC Invests $1.48 Million in Verona Pharma plc (NASDAQ:VRNA)June 5 at 5:11 AM | marketbeat.comHennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)June 3, 2025 | marketbeat.comHamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)June 3, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockJune 3, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst UpgradeJune 3, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst UpgradeJune 2, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC WainwrightJune 2, 2025 | marketbeat.comTwo Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)June 2, 2025 | marketbeat.com7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust CorpJune 2, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DEJune 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?June 1, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 SharesMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in StockMay 31, 2025 | marketbeat.comDavid Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 SharesMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 SharesMay 31, 2025 | marketbeat.comDavid Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?May 31, 2025 | marketbeat.com10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLCMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in StockMay 30, 2025 | insidertrades.comJim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”May 29, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueRenaissance Hedge Fund’s Biggest Q1 Buys RevealedBy Leo Miller | May 22, 2025View Renaissance Hedge Fund’s Biggest Q1 Buys RevealedTRIL, CORT, BBIO, and VRNA Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$38.62 +0.28 (+0.73%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$38.62 +0.01 (+0.01%) As of 06/6/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Corcept Therapeutics NASDAQ:CORT$69.60 +0.59 (+0.85%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$70.80 +1.20 (+1.72%) As of 06/6/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Trillium Therapeutics NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Verona Pharma NASDAQ:VRNA$84.34 -1.20 (-1.40%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$83.98 -0.36 (-0.43%) As of 06/6/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
